PT1496865E - Processo para a preparacao de cristais, cristais assim obtidos e sua utilizacao em formulacoes farmaceuticas - Google Patents

Processo para a preparacao de cristais, cristais assim obtidos e sua utilizacao em formulacoes farmaceuticas

Info

Publication number
PT1496865E
PT1496865E PT03730046T PT03730046T PT1496865E PT 1496865 E PT1496865 E PT 1496865E PT 03730046 T PT03730046 T PT 03730046T PT 03730046 T PT03730046 T PT 03730046T PT 1496865 E PT1496865 E PT 1496865E
Authority
PT
Portugal
Prior art keywords
crystals
mum
pharmaceutical formulations
preparing
benzaldoxim
Prior art date
Application number
PT03730046T
Other languages
English (en)
Inventor
Detlef Grawe
Gerecke Hagen
Hoesel Peter
Eichardt Annette
Gliesing Sabine
Mueller Uwe
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Publication of PT1496865E publication Critical patent/PT1496865E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0077—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 substituted in position 11-beta by a carbon atom, further substituted by a group comprising at least one further carbon atom
    • C07J41/0083—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 substituted in position 11-beta by a carbon atom, further substituted by a group comprising at least one further carbon atom substituted in position 11-beta by an optionally substituted phenyl group not further condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
PT03730046T 2002-04-23 2003-04-22 Processo para a preparacao de cristais, cristais assim obtidos e sua utilizacao em formulacoes farmaceuticas PT1496865E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10218109A DE10218109A1 (de) 2002-04-23 2002-04-23 Verfahren zum Herstellen von Kristallen, danach erhältliche Kristalle und deren Verwendung in pharmazeutischen Formulierungen

Publications (1)

Publication Number Publication Date
PT1496865E true PT1496865E (pt) 2006-10-31

Family

ID=29264788

Family Applications (1)

Application Number Title Priority Date Filing Date
PT03730046T PT1496865E (pt) 2002-04-23 2003-04-22 Processo para a preparacao de cristais, cristais assim obtidos e sua utilizacao em formulacoes farmaceuticas

Country Status (20)

Country Link
US (1) US7192942B2 (pt)
EP (1) EP1496865B1 (pt)
JP (1) JP4490114B2 (pt)
KR (1) KR20040106379A (pt)
CN (1) CN1646101A (pt)
AT (1) ATE332686T1 (pt)
AU (1) AU2003240652A1 (pt)
BR (1) BR0308744A (pt)
CA (1) CA2479991C (pt)
DE (2) DE10218109A1 (pt)
DK (1) DK1496865T3 (pt)
ES (1) ES2268368T3 (pt)
IL (1) IL163985A0 (pt)
MX (1) MXPA04010468A (pt)
NO (1) NO20045073L (pt)
PL (1) PL371339A1 (pt)
PT (1) PT1496865E (pt)
RU (1) RU2314315C2 (pt)
WO (1) WO2003090714A1 (pt)
ZA (1) ZA200409395B (pt)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10218107A1 (de) * 2002-04-23 2003-11-20 Jenapharm Gmbh Verfahren zum Herstellen von Kristallen von Steroiden, danach erhältliche Kristalle und deren Verwendung in pharmazeutischen Formulierungen
MX2008010707A (es) * 2006-03-14 2009-01-27 Merck & Co Inc Procesos y aparatos para la produccion de composiciones de microparticulas organicas cristalinas mediante micromolienda y cristalizacion sobre microsemilla y su uso.
DE102009034367A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-benzyliden-Derivate, Verfahren zu deren Herstellung und deren Verwendung zur Behandlung von Krankheiten
DE102009034366A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-methylenoxyalkylenaryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034368A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-acyloxyalkylenphenyl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034526A1 (de) 2009-07-21 2011-02-10 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-ethinylphenyl-Derivate, Verfahren zu deren Herstellung und deren Verwendung zur Behandlung von Krankheiten
DE102010007719A1 (de) 2010-02-10 2011-08-11 Bayer Schering Pharma Aktiengesellschaft, 13353 Progesteronrezeptorantagonisten
DE102010007722A1 (de) 2010-02-10 2011-08-11 Bayer Schering Pharma Aktiengesellschaft, 13353 Progesteronrezeptorantagonisten
RU2464321C2 (ru) * 2010-12-20 2012-10-20 Федеральное государственное образовательное учреждение высшего профессионального образования "Вологодская государственная молочнохозяйственная академия им. Н.В. Верещагина" Способ производства молочного сахара
EP3936133A1 (en) 2011-11-23 2022-01-12 TherapeuticsMD, Inc. Natural combination hormone replacement formulations and therapies
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
KR20170005819A (ko) 2014-05-22 2017-01-16 쎄러퓨틱스엠디, 인코퍼레이티드 천연 복합 호르몬 대체 제형 및 요법
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
AU2017239645A1 (en) 2016-04-01 2018-10-18 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations
US20230183205A1 (en) 2020-05-15 2023-06-15 Shionogi & Co., Ltd. Pharmaceutical composition in which production of impurities is suppressed

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DD275398B5 (de) 1988-09-07 1993-12-23 Dresden Arzneimittel Verfahren zur herstellung von feinverteilten pharmazeutischen wirkstoffen
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
NZ248813A (en) * 1992-11-25 1995-06-27 Eastman Kodak Co Polymeric grinding media used in grinding pharmaceutical substances
DE4332283A1 (de) * 1993-09-20 1995-04-13 Jenapharm Gmbh Neue 11-Benzaldoximestradien-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
DE69419151T2 (de) * 1993-12-27 1999-11-11 Nippon Soda Co 4-hydroxy-4'-isopropoxydiphenylsulfon-entwicklerzusammensetzungen, nasspulverisierungsverfahren und dispersion
US5718388A (en) * 1994-05-25 1998-02-17 Eastman Kodak Continuous method of grinding pharmaceutical substances
US5534270A (en) * 1995-02-09 1996-07-09 Nanosystems Llc Method of preparing stable drug nanoparticles
AU8145198A (en) 1997-06-16 1999-01-04 Vertex Pharmaceuticals Incorporated Methods of increasing the bioavailability of stable crystal polymorphs of a compound
US6582940B1 (en) * 1998-12-25 2003-06-24 Daiichi Fine Chemical Co., Ltd. Method for producing calcium pantothenate
EP1157996A1 (de) * 2000-05-23 2001-11-28 JENAPHARM GmbH Neue Festkörperformen des Mesoprogestins 11Beta-[4E-(Hydroxyiminomethyl)-phenyl]-17Alpha-methoxymethyl-17Beta-methoxy-estra-4,9-dien-3-on
DE10218107A1 (de) * 2002-04-23 2003-11-20 Jenapharm Gmbh Verfahren zum Herstellen von Kristallen von Steroiden, danach erhältliche Kristalle und deren Verwendung in pharmazeutischen Formulierungen

Also Published As

Publication number Publication date
EP1496865A1 (de) 2005-01-19
RU2314315C2 (ru) 2008-01-10
AU2003240652A1 (en) 2003-11-10
ATE332686T1 (de) 2006-08-15
JP4490114B2 (ja) 2010-06-23
RU2004134327A (ru) 2006-02-27
CN1646101A (zh) 2005-07-27
CA2479991A1 (en) 2003-11-06
JP2005523333A (ja) 2005-08-04
BR0308744A (pt) 2005-01-11
IL163985A0 (en) 2005-12-18
WO2003090714A1 (de) 2003-11-06
MXPA04010468A (es) 2004-12-13
US20030225050A1 (en) 2003-12-04
CA2479991C (en) 2010-06-22
EP1496865B1 (de) 2006-07-12
PL371339A1 (en) 2005-06-13
US7192942B2 (en) 2007-03-20
DE10218109A1 (de) 2003-11-20
KR20040106379A (ko) 2004-12-17
DK1496865T3 (da) 2006-10-09
ZA200409395B (en) 2006-02-22
NO20045073L (no) 2004-11-22
ES2268368T3 (es) 2007-03-16
DE50304230D1 (de) 2006-08-24

Similar Documents

Publication Publication Date Title
PT1496865E (pt) Processo para a preparacao de cristais, cristais assim obtidos e sua utilizacao em formulacoes farmaceuticas
RU94027576A (ru) Производные 1-бензолсульфонил-1,3-дигидро-индол-2-она, способ их получения и содержащие их фармацевтические композиции
CY1106383T1 (el) Νεες διφαινζυλαζητιδινονες, η διαδικασια για την παραγωγη τους, τα φαρμακευτικα παρασκευασματα που πepιεχουν τις ενωσεις τους καθως και η χρηση τους για την αντιμετωπιση των διαταραχων μεταβολισμου λιπιδιων
CL2007001286A1 (es) Procedimiento para preparar amidas aromaticas del acido crotonico por formacion delcloruro de acido correspondiente y amidacion posterior.
PT744941E (pt) Processo para preparar formulacoes farmaceuticas de particulas finas
BR9915420A (pt) Composto, composição farmacêutica, métodos de tratar um distúrbio mediado por tnf e por p38 cinase, inflamação e artrite e processo de preparar pirazóis
BR0307351A (pt) Composto, composição farmacêutica, método para tratar uma condição ou estado de doença mediados pela atividade de p38 quinase ou mediados por citocinas produzidas pela atividade de p38 quinase, uso de um composto, e, processo para preparar um composto
NO20012158L (no) Substituerte 2-fenylbenzimidazoler, fremgangsmåte til fremstilling og anvendelse derav
TNSN04199A1 (en) Acyl-4-carboxyphenylurea derivatives, processes for preparing them and their use
BRPI0411508A (pt) composto, formulação farmacêutica, uso de um composto, método para tratar doenças, e, processo para preparar um composto
DK297483A (da) Fremgangsmaade til fremstilling af derivater af 9-(2-hydroxyethoxymethyl)guanin
BR8606336A (pt) Derivados de pirazolina,processo para sua preparacao,composicoes inseticidas e emprego
NO20021859D0 (no) Nye digosakkarider, deres fremstilling samt farmasöytiske preparater
MA27232A1 (fr) Derives d'acide n-benzoylureidocinnamique, leurs procedes de preparation et leurs utilisations
DK1497308T3 (da) Fremgangsmåde til fremstilling af krystaller af steroider, krystaller opnået ved hjælp heraf og anvendelse heraf i farmaceutiske formuleringer
DK148183D0 (da) Fremgangsmade til fremstilling af imidazolylphenyl-tetrahydropyridaziner
PL352476A1 (en) Novel derivatives of piperazinylalkylthiopyrimidine, parmacological compositions containing tese compounds and method of obtaining active substance
BE895991A (fr) Nouvelles modifications cristallines, procede pour leur production, et preparations pharmaceutiques les contenant
EP1420028A3 (fr) Pocédé de synthèse du perindopril et de ses sels pharmaceutiquement acceptables
NO983860L (no) Nye triazolopuriner, fremgangsmÕte for deres fremstilling og deres anvendelse som legemidler
MA27805A1 (fr) Cristaux de derive de benzimidazole et leur procede de preparation
DK23887A (da) Benzimidazolderivater
DK0505400T3 (da) N-substituerede naphthalimider, deres fremstilling og anvendelse
DK218388A (da) Aktivt princip isoleret fra hajvaev
NO20045071L (no) Fremgangsmate for fremstilling av krystaller ut i fra aktive legemiddelvirkestoffer, krystaller oppnadd derav og deres anvendelse i farmasoytiske formuleringer